Chapter 10 of 25
- POLEmut: qualifying pathogenic proofreading mutation
- MMRd: defective DNA mismatch repair
- p53abn: abnormal p53 biology after classifier integration
- NSMP: none of the other groups; grade and ER refine risk
What you will learn
- Distinguish tumour testing from inherited, or germline, testing.
- Understand MMR proteins, methylation, MSI, POLE, p53, ER/PR and HER2.
- Know which findings need specialist interpretation.
MMR proteins and MSI
Immunohistochemistry is a laboratory stain that checks whether specific proteins are present in tumour cells. The four commonly assessed mismatch repair proteins are MLH1, PMS2, MSH2 and MSH6. Their loss patterns can guide further testing. MSI testing instead examines repeated DNA sequences for instability; it assesses a related consequence of defective repair.
MMR testing is broadly recommended in endometrial cancer because it informs molecular classification, systemic treatment options and Lynch screening. Discordant or technically uncertain results need pathology review, and sometimes a second method. Do not assume two apparently different reports necessarily mean the tumour changed.
MLH1 methylation and Lynch syndrome
When MLH1, often with PMS2, is lost, MLH1 promoter methylation testing can help identify an acquired silencing mechanism. Methylation commonly points toward a sporadic tumour. Unmethylated MLH1 loss, MSH2/MSH6 loss or isolated PMS2 loss usually warrants genetic counselling and consideration of germline testing.
A strong personal or family history can still justify genetics assessment despite methylation or retained MMR staining. Germline testing usually uses blood or saliva to look for inherited variants. A positive tumour test alone does not diagnose Lynch syndrome; two acquired tumour changes can sometimes explain repair deficiency without inherited disease.
Other classification and treatment tests
| Test | Main purpose | Important limitation |
|---|---|---|
| POLE sequencing | Identify qualifying proofreading-region mutations | Uncertain variants do not establish the favourable group |
| p53 immunohistochemistry | Help identify p53-abnormal biology | Pattern and technical controls matter |
| ER/PR | Assess hormone-receptor expression; ER also refines NSMP risk | Positivity does not guarantee hormonal response |
| HER2 | Identify selected cancers that may benefit from HER2-directed therapy | Assay, score, histology and treatment indication must match |
| Broader sequencing | Look for selected actionable alterations or trial options | Many findings are not actionable |
ER testing has a broader role in contemporary risk assessment, while PR may support selected hormonal-treatment decisions. HER2 testing is particularly relevant in appropriate advanced or recurrent serous, p53-abnormal or carcinosarcoma settings. Different HER2 medicines can require different eligibility thresholds; “HER2-low” is not interchangeable with an approved HER2 IHC 3+ tumour-agnostic indication.
What is routine and what is selective?
A complete molecular classification is encouraged where feasible, especially when it can change postoperative treatment. Access and local pathways differ; some low-risk situations use a selective POLE-testing strategy. Ask what information is missing and whether obtaining it would alter care. Universal large-panel sequencing is not a substitute for properly performed core pathology tests.
PD-L1 CPS, used in some other cancers, is not generally the selection requirement for the main endometrial chemo-immunotherapy or lenvatinib–pembrolizumab indications discussed in this guide. A negative PD-L1 result should not be interpreted in isolation as ruling out all immunotherapy options.
Questions, privacy and family implications
Before germline testing, discuss possible results, uncertain variants, family communication, costs and local privacy protections. A confirmed inherited pathogenic variant can guide testing of relatives; an uncertain variant should not automatically trigger preventive surgery. Ask for a written genetics summary and who will arrange any recommended colorectal or other surveillance.
Related chapters
- FIGO Staging of Endometrial Cancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- ESGO consensus on endometrial prevention and Lynch syndrome, 2026
- GeneReviews: Lynch Syndrome
- FDA pembrolizumab–chemotherapy approval / KEYNOTE-868, June 2024
- DailyMed: Lenvima prescribing information
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy